EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment

Kaenat Mulla, Sheima Farag, Benedict Moore, Sheila Matharu, Kate Young, James Larkin, Sanjay Popat, Daniel Laurence Morganstein iD

Diabetic Medicine · 2023-04 · 40 (4)

DOI: 10.1111/dme.15053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 06.02.2023. Verfasst von Kaenat Mulla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beta Cell Diabetes Unit, Chelsea and Westminster Hospital, London, UK. Hauptthemen laut MEDLINE: Hyperglycemia, Diabetes Mellitus, Type 1, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new‐onset hyperglycaemia, Methods Retrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.

Results

Overall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new‐onset hyperglycaemia (without pre‐existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.

Conclusions

Hyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI‐induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperglycemiaDiabetes Mellitus, Type 1Lung NeoplasmsHumansImmune Checkpoint InhibitorsIncidence

Stichwörter der Autor:innen

cancerclinical diabetes

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Beta Cell Diabetes Unit, Chelsea and Westminster Hospital, London, UK.
  • Skin Unit, Royal Marsden Hospital, London, UK.
  • Data Unit, Royal Marsden Hospital, London, UK.
  • Lung Unit, Royal Marsden Hospital, London, UK.

ORCID-Profile: Daniel Laurence Morganstein

Zitieren

APA

Mulla, K., Farag, S., Moore, B., Matharu, S., Young, K., Larkin, J., Popat, S., & Morganstein, D. L. (2023). Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabetic Medicine, 40(4). https://doi.org/10.1111/dme.15053

Vancouver

Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, et al. Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabetic Medicine. 2023;40(4). doi:10.1111/dme.15053

BibTeX
@article{Mulla2023,
  author = {Mulla, Kaenat and Farag, Sheima and Moore, Benedict and Matharu, Sheila and Young, Kate and Larkin, James and Popat, Sanjay and Morganstein, Daniel Laurence},
  title = {Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment},
  journal = {Diabetic Medicine},
  year = {2023},
  volume = {40},
  number = {4},
  doi = {10.1111/dme.15053}
}
Kostenlos starten →